Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at kfgo.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

Orbis Medicines has entered a drug discovery and licensing deal worth up to $1.4 billion with Novo Nordisk to develop oral therapies for cardiometabolic diseases using AI-enabled macrocycle drug discovery.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

AI-driven oral drug discovery is shifting cardiometabolic treatment options away from injections. If you develop peptide therapies, accelerating oral delivery methods just opened a strategic path to market.

◆ Coverage

2 sources · 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechoral-therapiescardiometabolicai-drug-discoverymacrocyclespharma-collaboration